| COMPANY |
Cassava Sciences, Inc. |
| COURT |
United States District Court for the Western District of Texas |
| CASE NUMBER |
24-cv-01525 |
| JUDGE |
The Honorable David A. Ezra |
| CLASS PERIOD |
October 13, 2023 through March 25, 2025 |
| SECURITY TYPE |
Securities |
Case Background:
This is a securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Cassava Sciences Inc. (“Cassava”) (NASDAQ: SAVA) securities between October 13, 2023 through March 25, 2025, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Cassava’s drug, simufilam, was not capable of abating the progression of Alzheimer’s Disease, even in mild to moderate cases; and (2) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On August 25, 2025, Plaintiffs filed an Amended Complaint. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.